Long-term clinical study reports outcomes of lipid-lowering therapy in heterozygous familial hypercholesterolaemia, indicating sustained treatment patterns over 15 years.
Key Points
To review the long-term clinical history and outcomes of lipid-lowering therapy in individuals diagnosed with heterozygous familial hypercholesterolaemia over a 15-year period.
Assessed clinical management and therapeutic responses to lipid-lowering drugs in patients with heterozygous familial hypercholesterolaemia over 15 years of follow-up.